[1]
|
World Health Organization (2006) The Selection and Use of Essential Medicines: Report of the WHO Expert Committee, 2005; (Including the 14th Model List of Essential Medicines); [WHO Expert Committee on the Selection and Use of Essential Medicines, Geneva, 7-11 March 2005]. World Health Organization, Geneva.
|
[2]
|
Franco, P. (2013) Orphan Drugs: The Regulatory Environment. Drug Discovery Today, 18, 163-172. https://doi.org/10.1016/j.drudis.2012.08.009
|
[3]
|
Arno, P.S., Bonuck, K. and Davis, M. (1995) Rare Diseases, Drug Development, and AIDS: The Impact of the Orphan Drug Act. The Milbank Quarterly, 73, 231-252. https://doi.org/10.2307/3350258
|
[4]
|
马端, 李定国, 张学. 中国罕见病防治的机遇与挑战[J]. 中国循证儿科杂志, 2011, 6(2): 81-82.
|
[5]
|
Richter, T., Nestler-Parr, S., Babela, R., et al. (2015) Rare Disease Terminology and Definitions—A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 18, 906-914. https://doi.org/10.1016/j.jval.2015.05.008
|
[6]
|
Nguengang, W.S., Lambert, D.M., Olry, A., et al. (2020) Estimating Cumulative Point Prevalence of Rare Diseases: Analysis of the Orphanet Database. European Journal of Human Genetics: EJHG, 28, 165-173. https://doi.org/10.1038/s41431-019-0508-0
|
[7]
|
Ferreira, C.R. (2019) The Burden of Rare Diseases. American Journal of Medical Genetics. Part A, 179, 885-892. https://doi.org/10.1002/ajmg.a.61124
|
[8]
|
Hall, J.G., Powers, E.K., Mcllvaine, R.T., et al. (1978) The Frequency and Financial Burden of Genetic Disease in a Pediatric Hospital. American Journal of Medical Genetics, 1, 417-436. https://doi.org/10.1002/ajmg.1320010405
|
[9]
|
Yoon, P.W. (1997) Contribution of Birth Defects and Genetic Diseases to Pediatric Hospitalizations: A Population-Based Study. Archives of Pediatrics & Adolescent Medicine, 151, 1096-1103. https://doi.org/10.1001/archpedi.1997.02170480026004
|
[10]
|
Angelis, A., Tordrup, D. and Kanavos, P. (2015) Socio-Economic Burden of Rare Diseases: A Systematic Review of Cost of Illness Evidence. Health Policy (Amsterdam, Netherlands), 119, 964-979. https://doi.org/10.1016/j.healthpol.2014.12.016
|
[11]
|
Cohen, J.S. and Biesecker, B.B. (2010) Quality of Life in Rare Genetic Conditions: A Systematic Review of the Literature. American Journal of Medical Genetics. Part A, 152, 1136-1156. https://doi.org/10.1002/ajmg.a.33380
|
[12]
|
Pelentsov, L.J., Fielder, A.L., Laws, T.A., et al. (2016) The Supportive Care Needs of Parents with a Child with a Rare Disease: Results of an Online Survey. BMC Family Practice, 17, Article No. 88. https://doi.org/10.1186/s12875-016-0488-x
|
[13]
|
The Lancet Diabetes Endocrinology (2019) Spotlight on Rare Diseases. The Lancet. Diabetes & Endocrinology, 7, 75. https://doi.org/10.1016/S2213-8587(19)30006-3
|
[14]
|
Kvarnung, M. and Nordgren, A. (2017) Intellectual Disability & Rare Disorders: A Diagnostic Challenge. In: de la Paz, M.P., Taruscio, D. and Groft, S.C., Eds., Rare Diseases Epidemiology: Update and Overview, Springer, Berlin, 39-54. https://doi.org/10.1007/978-3-319-67144-4_3
|
[15]
|
Almalki, Z.S., Alahmari, A.K., Guo, J.J., et al. (2012) Access to Orphan Drugs in the Middle East: Challenge and Perspective. Intractable & Rare Diseases Research, 1, 139-143. https://doi.org/10.5582/irdr.2012.v1.4.139
|
[16]
|
Giovannini, M., Luzzati, M., Ferrara, G., et al. (2018) Common Symptoms for a Rare Disease in a Girl with Sarcoidosis: A Case Report. Italian Journal of Pediatrics, 44, Article No. 74. https://doi.org/10.1186/s13052-018-0517-6
|
[17]
|
Girirajan, S., Rosenfeld, J.A., Coe, B.P., et al. (2012) Phenotypic Heterogeneity of Genomic Disorders and Rare Copy-Number Variants. The New England Journal of Medicine, 367, 1321-1331. https://doi.org/10.1056/NEJMoa1200395
|
[18]
|
Anderson, M., Elliott, E.J. and Zurynski, Y.A. (2013) Australian Families Living with Rare Disease: Experiences of Diagnosis, Health Services Use and Needs for Psychosocial Support. Orphanet Journal of Rare Diseases, 8, Article No. 22. https://doi.org/10.1186/1750-1172-8-22
|
[19]
|
Zurynski, Y., Deverell, M., Dalkeith, T., et al. (2017) Australian Children Living with Rare Diseases: Experiences of Diagnosis and Perceived Consequences of Diagnostic Delays. Orphanet Journal of Rare Diseases, 12, Article No. 68. https://doi.org/10.1186/s13023-017-0622-4
|
[20]
|
Kempf, L., Goldsmith, J.C. and Temple, R. (2018) Challenges of Developing and Conducting Clinical Trials in Rare Disorders. American Journal of Medical Genetics. Part A, 176, 773-783. https://doi.org/10.1002/ajmg.a.38413
|
[21]
|
Asbury, C.H. (1991) The Orphan Drug Act. The First 7 Years. JAMA, 265, 893-897. https://doi.org/10.1001/jama.1991.03460070075046
|
[22]
|
Fantini, B. and Vaccaro, C.M. (2019) Value Based Healthcare for Rare Diseases: Efficiency, Efficacy, Equity. Annali Dell’Istituto Superiore Di Sanita, 55, 251-257.
|
[23]
|
Ahmed, M.A., Okour, M., Brundage, R., et al. (2019) Orphan Drug Development: The Increasing Role of Clinical Pharmacology. Journal of Pharmacokinetics and Pharmacodynamics, 46, 395-409. https://doi.org/10.1007/s10928-019-09646-3
|
[24]
|
Divino, V., DeKoven, M., Kleinrock, M., et al. (2016) Orphan Drug Expenditures in the United States: A Historical and Prospective Analysis, 2007-18. Health Affairs (Project Hope), 35, 1588-1594. https://doi.org/10.1377/hlthaff.2016.0030
|
[25]
|
Senior, M. (2022) Orphan Drugs: From Niche to Mainstream. MJH Life Sciences, 42, 32-33.
|
[26]
|
Kölker, S., Gleich, F., Mütze, U., et al. (2022) Rare Disease Registries Are Key to Evidence-Based Personalized Medicine: Highlighting the European Experience. Frontiers in Endocrinology, 13, Article ID: 832063. https://doi.org/10.3389/fendo.2022.832063
|
[27]
|
张波, 张抒扬, 屈静晗, 等. 多准则决策分析应用于罕见病药品临床综合评价的专家共识(2022) [J]. 罕见病研究, 2022, 1(2): 158-177.
|
[28]
|
Marwaha, S., Knowles, J.W. and Ashley, E.A. (2022) A Guide for the Diagnosis of Rare and Undiagnosed Disease: Beyond the Exome. Genome Medicine, 14, Article No. 23. https://doi.org/10.1186/s13073-022-01026-w
|
[29]
|
顾学范, 韩连书, 余永国. 中国新生儿遗传代谢病筛查现状及展望[J]. 罕见病研究, 2022, 1(1): 13-19.
|
[30]
|
Fernández-Marmiesse, A., Gouveia, S. and Couce, M.L. (2018) NGS Technologies as a Turning Point in Rare Disease Research, Diagnosis and Treatment. Current Medicinal Chemistry, 25, 404-432. https://doi.org/10.2174/0929867324666170718101946
|
[31]
|
Souche, E., Beltran, S., Brosens, E., et al. (2022) Recommendations for Whole Genome Sequencing in Diagnostics for Rare Diseases. European Journal of Human Genetics, 30, 1017-1021. https://doi.org/10.1038/s41431-022-01113-x
|
[32]
|
Choi, M., Scholl, U.I., Ji, W., et al. (2009) Genetic Diagnosis by Whole Exome Capture and Massively Parallel DNA Sequencing. Proceedings of the National Academy of Sciences of the United States of America, 106, 19096-19101. https://doi.org/10.1073/pnas.0910672106
|
[33]
|
Neveling, K., Feenstra, I., Gilissen, C., et al. (2013) A Post-Hoc Comparison of the Utility of Sanger Sequencing and Exome Sequencing for the Diagnosis of Heterogeneous Diseases. Human Mutation, 34, 1721-1726. https://doi.org/10.1002/humu.22450
|
[34]
|
喻长顺, 于世辉. 罕见病及其基因诊断的发展现状[J]. 海南医学, 2019, 30(S1): 56-67.
|
[35]
|
Lunke, S., Bouffler, S.E., Patel, C.V., et al. (2023) Integrated Multi-Omics for Rapid Rare Disease Diagnosis on a National Scale. Nature Medicine, 29, 1681-1691. https://doi.org/10.1038/s41591-023-02401-9
|
[36]
|
Birgmeier, J., Haeussler, M., Deisseroth, C.A., et al. (2020) AMELIE Speeds Mendelian Diagnosis by Matching Patient Phenotype and Genotype to Primary Literature. Science Translational Medicine, 12, Eaau9113. https://doi.org/10.1126/scitranslmed.aau9113
|
[37]
|
Sundaram, L., Gao, H., Padigepati, S.R., et al. (2018) Predicting the Clinical Impact of Human Mutation with Deep Neural Networks. Nature Genetics, 50, 1161-1170. https://doi.org/10.1038/s41588-018-0167-z
|
[38]
|
Jaganathan, K., Panagiotopoulou, S.K., McRae, J.F., et al. (2019) Predicting Splicing from Primary Sequence with Deep Learning. Cell, 176, 535-548.E24. https://doi.org/10.1016/j.cell.2018.12.015
|
[39]
|
Brasil, S., Pascoal, C., Francisco, R., et al. (2019) Artificial Intelligence (AI) in Rare Diseases: Is the Future Brighter? Genes, 10, Article No. 978. https://doi.org/10.3390/genes10120978
|
[40]
|
Carter, H., Douville, C., Stenson, P.D., et al. (2013) Identifying Mendelian Disease Genes with the Variant Effect Scoring Tool. BMC Genomics, 14, S3. https://doi.org/10.1186/1471-2164-14-S3-S3
|
[41]
|
Alirezaie, N., Kernohan, K.D., Hartley, T., et al. (2018) ClinPred: Prediction Tool to Identify Disease-Relevant Nonsynonymous Single-Nucleotide Variants. American Journal of Human Genetics, 103, 474-483. https://doi.org/10.1016/j.ajhg.2018.08.005
|
[42]
|
Orange, J.S., Glessner, J.T., Resnick, E., et al. (2011) Genome-Wide Association Identifies Diverse Causes of Common Variable Immunodeficiency. The Journal of Allergy and Clinical Immunology, 127, 1360-1367.E6. https://doi.org/10.1016/j.jaci.2011.02.039
|
[43]
|
Liehr, T., Acquarola, N., Pyle, K., et al. (2018) Next Generation Phenotyping in Emanuel and Pallister-Killian Syndrome Using Computer-Aided Facial Dysmorphology Analysis of 2D Photos. Clinical Genetics, 93, 378-381. https://doi.org/10.1111/cge.13087
|
[44]
|
Hoy, S.M. (2019) Elexacaftor/Ivacaftor/Tezacaftor: First Approval. Drugs, 79, 2001-2007. https://doi.org/10.1007/s40265-019-01233-7
|
[45]
|
Oldenburg, J., Mahlangu, J.N., Kim, B., et al. (2017) Emicizumab Prophylaxis in Hemophilia A with Inhibitors. The New England Journal of Medicine, 377, 809-818. https://doi.org/10.1056/NEJMoa1703068
|
[46]
|
Tambuyzer, E., Vandendriessche, B., Austin, C.P., et al. (2020) Therapies for Rare Diseases: Therapeutic Modalities, Progress and Challenges Ahead. Nature Reviews. Drug Discovery, 19, 93-111. https://doi.org/10.1038/s41573-019-0049-9
|
[47]
|
Li, C. and Samulski, R.J. (2020) Engineering Adeno-Associated Virus Vectors for Gene Therapy. Nature Reviews Genetics, 21, 255-272. https://doi.org/10.1038/s41576-019-0205-4
|
[48]
|
Scott, L.J. (2015) Alipogene Tiparvovec: A Review of Its Use in Adults with Familial Lipoprotein Lipase Deficiency. Drugs, 75, 175-182. https://doi.org/10.1007/s40265-014-0339-9
|
[49]
|
Shahryari, A., Saghaeian, J.M., Mohammadi, S., et al. (2019) Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders. Frontiers in Genetics, 10, Article No. 868. https://doi.org/10.3389/fgene.2019.00868
|
[50]
|
Smalley, E. (2017) First AAV Gene Therapy Poised for Landmark Approval. Nature Biotechnology, 35, 998-999. https://doi.org/10.1038/nbt1117-998
|
[51]
|
Cavazzana-Calvo, M., Payen, E., Negre, O., et al. (2010) Transfusion Independence and HMGA2 Activation after Gene Therapy of Human β-Thalassaemia. Nature, 467, 318-322. https://doi.org/10.1038/nature09328
|
[52]
|
Aiuti, A., Slavin, S., Aker, M., et al. (2002) Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning. Science (New York, N.Y.), 296, 2410-2413. https://doi.org/10.1126/science.1070104
|
[53]
|
Garrelfs, S.F., Frishberg, Y., Hulton, S.A., et al. (2021) Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. The New England Journal of Medicine, 384, 1216-1226. https://doi.org/10.1056/NEJMoa2021712
|
[54]
|
Pai, S.-Y., Logan, B.R., Griffith, L.M., et al. (2014) Transplantation Outcomes for Severe Combined Immunodeficiency, 2000-2009. The New England Journal of Medicine, 371, 434-446. https://doi.org/10.1056/NEJMoa1401177
|
[55]
|
Chan, J.K.Y. and Götherström, C. (2014) Prenatal Transplantation of Mesenchymal Stem Cells to Treat Osteogenesis Imperfecta. Frontiers in Pharmacology, 5, Article No. 223. https://doi.org/10.3389/fphar.2014.00223
|
[56]
|
Schwartz, S.D., Regillo, C.D., Lam, B.L., et al. (2015) Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium in Patients with Age-Related Macular Degeneration and Stargardt’s Macular Dystrophy: Follow-Up of Two Open-Label Phase 1/2 Studies. The Lancet (London, England), 385, 509-516. https://doi.org/10.1016/S0140-6736(14)61376-3
|